SingleMetabolic / GLP-1

Retatrutide 6mg

First-in-class triple agonist peptide targeting GLP-1, GIP, and glucagon receptors for profound metabolic and weight regulation research.

Mechanism

Retatrutide acts as a unimolecular triple agonist targeting the GLP-1, GIP, and glucagon receptors to synergistically enhance satiety, optimize glucose regulation, and augment energy expenditure.

Dosing

Documented laboratory investigations initiate the peptide at a starting dose of 2 mg administered subcutaneously once per week.

Reconstitution

Reconstituting a 6 mg vial with 1.2 mL of bacteriostatic water yields an operational working concentration of 5 mg/mL.

Storage

Store the unmixed lyophilized powder frozen at -20 °C, and once reconstituted, maintain the solution refrigerated at 2–8 °C for up to 4 weeks shielded from light.

Mix & measure Retatrutide 6mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Retatrutide 6mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration5.00mg/mL

Draw volume0.400mL

On the syringe40.0units

Total doses in vial: 3.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	2 mg once weekly	40 units (0.40 mL)
Weeks 5–8	4 mg once weekly	80 units (0.80 mL)
Weeks 9–12	8 mg once weekly	160 units (1.60 mL) — requires 2 vials
Weeks 13+	12 mg once weekly	240 units (2.40 mL) — requires 2 vials

Reconstitution Steps

1
Draw exactly 1.2 mL of bacteriostatic water into a sterile syringe.
2
Introduce the needle into the 6 mg vial and discharge the diluent slowly down the glass wall to minimize agitation.
3
Gently rotate and swirl the vial until the lyophilized cake is entirely dissolved without vigorously shaking.
4
Record the date of reconstitution and place the solution in refrigeration at 2–8 °C protected from light exposure.

Supplies Needed

Peptide Vial

Lyophilized retatrutide 6 mg powder intended for reconstituting research solutions.

Insulin Syringes (U-100)

Precision U-100 (1 mL) syringes used for accurate dosing volume measurement and subcutaneous delivery.

Bacteriostatic Water

Sterile diluent containing 0.9% benzyl alcohol utilized to reconstitute the peptide cake.

Alcohol Swabs

Disinfectant wipes applied to sanitize vial rubber stoppers and clean targeted administration sites.

Why researchers study it

Investigation of substantial body-weight reduction via triple-receptor agonism

Appetite suppression and modulation of food intake through GLP-1 and GIP signaling

Glycemic regulation and metabolic parameter management in diabetes models

Reduction of hepatic steatosis through targeted glucagon receptor activation

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Retatrutide is an investigational multi-incretin mimetic engineered to simultaneously engage three key metabolic pathways: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. By coordinating signaling across these distinct endocrine axes, the compound drives synergistic alterations in appetite suppression, insulin sensitivity, and resting energy expenditure. Preclinical models and clinical investigations highlight retatrutide as a significant progression beyond single- and dual-incretin receptor agonists. Its distinct inclusion of glucagon receptor agonism promotes enhanced hepatic lipid metabolism and thermogenesis, addressing core drivers of metabolic dysfunction without sacrificing glycemic balance. Due to an optimized molecular structure that provides an elimination half-life of approximately six days, retatrutide is routinely studied via once-weekly subcutaneous administrations. Research protocols emphasize deliberate, multi-week dose titration schedules to assess sustained metabolic shifts while optimizing subject tolerability throughout extended investigational courses.

References

1.Jastreboff et al., New England Journal of Medicine, 2023 — Triple-Hormone-Receptor Agonist Retatrutide for Obesity
2.Rosenstock et al., The Lancet, 2023 — Retatrutide in type 2 diabetes: Phase 2 trial
3.Frias et al., JAMA Network, 2023 — Retatrutide Phase 2 Obesity Trial: detailed efficacy and safety data
4.Metabolites (PMC), 2025 — Retatrutide—A Game Changer in Obesity Pharmacotherapy
5.Baylor University Medical Center Proceedings, 2025 — Efficacy and safety of retatrutide for obesity: meta-analysis of RCTs